109 related articles for article (PubMed ID: 15548851)
21. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods.
Chun AH; Erdman K; Zhang Y; Achari R; Cavanaugh JH
Clin Ther; 2000 Feb; 22(2):231-6. PubMed ID: 10743982
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Asaka M; Sugiyama T; Kato M; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S
Helicobacter; 2001 Sep; 6(3):254-61. PubMed ID: 11683930
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
24. Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Sugiyama T; Hisano K; Ochiai T; Fujita N; Kobayashi T; Yabana T; Kurokawa I; Yachi A
J Clin Gastroenterol; 1995; 20 Suppl 2():S104-6. PubMed ID: 7594322
[TBL] [Abstract][Full Text] [Related]
25. Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers.
Hussein RF; Lockyer M; Hammami MM
Arzneimittelforschung; 2007; 57(2):101-5. PubMed ID: 17396620
[TBL] [Abstract][Full Text] [Related]
26. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube.
Chun AH; Shi HH; Achari R; Dennis S; Cavanaugh JH
Clin Ther; 1996; 18(5):833-42. PubMed ID: 8930427
[TBL] [Abstract][Full Text] [Related]
27. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.
Sharma VK; Peyton B; Spears T; Raufman JP; Howden CW
Aliment Pharmacol Ther; 2000 Jul; 14(7):887-92. PubMed ID: 10886044
[TBL] [Abstract][Full Text] [Related]
28. Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers.
Dugger HA; Carlson JD; Henderson W; Erdmann GR; Alam SM; Dham R; Quamruzaman
Eur J Pharm Biopharm; 2001 Mar; 51(2):153-7. PubMed ID: 11226823
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
30. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
32. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
Devlin JW; Bakshi A; Bungay K; Olsen KM
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1603-11. PubMed ID: 17206948
[TBL] [Abstract][Full Text] [Related]
33. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
34. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
[TBL] [Abstract][Full Text] [Related]
35. Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers.
Joti JJ; Nahar K; Hasan A; Azad MA; Ullah MA; Islam SM; Hasnat A
Arzneimittelforschung; 2009; 59(4):171-5. PubMed ID: 19517893
[TBL] [Abstract][Full Text] [Related]
36. High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies.
Pandya KK; Mody VD; Satia MC; Modi IA; Modi RI; Chakravarthy BK; Gandhi TP
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):199-204. PubMed ID: 9200535
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Gremse D; Winter H; Tolia V; Gunasekaran T; Pan WJ; Karol M; Chiu YL; Pilmer B; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S319-26. PubMed ID: 12607792
[TBL] [Abstract][Full Text] [Related]
39. Lansoprazole: an alternative method of administration of a capsule dosage formulation.
Chun AH; Eason CJ; Shi HH; Cavanaugh JH
Clin Ther; 1995; 17(3):441-7. PubMed ID: 7585848
[TBL] [Abstract][Full Text] [Related]
40. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
